Long-Term Outcomes and Durability of a Novel Dedicated Transcatheter Heart Valve to Treat Native Aortic Regurgitation

Hanad Bashir; Gustavo Mendez-Hirata; Amy E Simone; Santiago Garcia; Dean J Kereiakes

doi:10.1016/j.jaccas.2024.102670

Long-Term Outcomes and Durability of a Novel Dedicated Transcatheter Heart Valve to Treat Native Aortic Regurgitation

JACC Case Rep. 2024 Nov 6;29(21):102670. doi: 10.1016/j.jaccas.2024.102670.

Authors

Hanad Bashir¹, Gustavo Mendez-Hirata¹, Amy E Simone², Santiago Garcia¹, Dean J Kereiakes¹

Affiliations

¹ The Christ Hospital Heart and Vascular Institute and Edyth Lindner Center for Research and Education, Cincinnati, Ohio, USA.
² JC Medical, Inc, Burlingame, California, USA.

Abstract

There is no Food and Drug Administration-approved dedicated transcatheter heart valve to treat native aortic regurgitation. Currently available data from ongoing clinical trials and compassionate use experiences in the United States provide echocardiographic and clinical outcomes to 1-year postprocedure. The case presents a 28-year-old man with severe aortic regurgitation successfully treated with J-Valve in 2019 (JC Medical, Inc). Long-term (5-year) outcomes demonstrate sustained valve hemodynamics and clinical stability, highlighting J-Valve as a promising minimally invasive alternative to surgery for high-risk patients with native aortic regurgitation.

Keywords: aortic regurgitation; transcatheter aortic valve replacement; transcatheter heart valve.

Publication types

Case Reports